3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
4
Sarcoma
2
Lymphoid
2
Head & Neck
2
Genitourinary
2
Endocrine
2
Dermatologic
2
Thoracic
1
Other hematologic neoplasm
1
NET
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Melanoma
3
Brain Neoplasms
2
Uveal Melanoma
1
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Noonan Syndrome 6
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma, Large-Cell, Anaplastic
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Radiosurgery
22
Ipilimumab
17
Nivolumab
16
pembrolizumab
11
Temozolomide
9
encorafenib
8
dabrafenib
8
binimetinib
8
Magnetic Resonance Spectroscopy
6
trametinib
5
Bevacizumab
5
CTLA-4 Antigen
4
cobimetinib
3
Thalidomide
3
Radiotherapy
3
Paclitaxel
3
entrectinib
2
cediranib
2
Vemurafenib
2
Spermine Synthase
2
Specimen Handling
2
Radiation
2
Pemetrexed
2
Opdualag
2
Drug Therapy
2
Carboplatin
2
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
2
14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione
2
130-nm albumin-bound paclitaxel
2
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
entrectinib
×
Dermatologic
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT05770544
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled